=Teva Pharma (TEVA) responds to Mylan (MYL) approval of a generic version of COPAXONE

Teva Pharma responds to Mylan (MYL) approval of a generic version of COPAXONE 40mg/ml, says any launch by Mylan of a generic version of COPAXONE 40mg/ml prior to final resolution of the pending patent appeals and other patent litigation should be considered an 'at-risk' launch

The co commented that any launch by Mylan of a generic version of COPAXONE 40mg/ml (glatiramer acetate) prior to final resolution of the pending patent appeals and other patent litigation should be considered an "at-risk" launch, which could subject Mylan to significant damages among other remedies. Additionally, Mylan also announced approval of a generic glatiramer acetate 20mg/mL.

• Two appeals will be argued before a single panel of judges of the U.S. Court of Appeals for the Federal Circuit. In the first case, Teva is appealing the December 2016 inter partes review decisions of the Patent Trial Appeal Board that found all of the claims of three COPAXONE patents to be unpatentable. In the second case, Teva is appealing the January 2017 decision of the U.S. District Court for the District of Delaware, which declared certain claims of four COPAXONE patents invalid. The two appeals have been fully briefed and await the scheduling of oral arguments. In additional litigation, Teva brought suit against five Abbreviated New Drug Application (ANDA) filers, including Mylan, for infringement of a patent covering a manufacturing process for glatiramer acetate product.
• Due to the anticipated launch of another generic 20mg glatiramer acetate product and the anticipated launch of a first generic 40mg glatiramer acetate product, Teva's early assessment of the impact of these launches to its earnings for the fourth quarter ended December 31, 2017 is that it could be affected by at least $0.25 cents per share.These conditions are subject to change based on the discount; adoption rate; and other factors of the competitive products.